Immunotherapy

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

By

Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.

Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura

Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura

By

Results of a retrospective single-center study showed that response to rituximab vs splenectomy as second-line therapy for steroid-refractory ITP was not significantly different between the 2 treatments.

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

By

Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.

Cannabis Reduces Response Rate to Immunotherapy for Cancer

Cannabis Reduces Response Rate to Immunotherapy for Cancer

By

Investigators report that administering cannabis to patients with cancer undergoing immunotherapy was found to lower the response rate to therapy but had no effect on PFS or OS, in an oral presentation at ESMO 2017 Congress.

Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications

Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications

By

Patients with multiple myeloma treated with daratumumab who experience IRRs may easily be managed by administering pre-infusion and postinfusion medications, investigators reported in a presentation at ESMO 2017 Congress.

Two FDA Approvals Propel CAR T Cell Therapy Into the Limelight

Two FDA Approvals Propel CAR T Cell Therapy Into the Limelight

By

The first FDA approval of a CAR T cell therapy is granted for the treatment of B-cell precursor ALL. FDA also approves rheumatoid arthritis medication for the management of cytokine release syndrome, a common and serious adverse effect of CAR T cell therapy

Affect of Daratumumab on Laboratory Blood Test Results

Affect of Daratumumab on Laboratory Blood Test Results

By

Do monoclonal antibodies other than daratumumab cause false positives in the blood antibody screen and crossmatch obtained prior to a transfusion?

Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia

Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia

By

Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

By

In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.

Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma

Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma

By

Immunotherapy regimens FDA-approved for the treatment of melanoma may also be an option for a rare and aggressive form of papillary thyroid cancer.

Evolving Education Initiative Keeps Nurses Up-to-Date on CAR T Cell Therapy Best Practices

Evolving Education Initiative Keeps Nurses Up-to-Date on CAR T Cell Therapy Best Practices

By

A multidisciplinary education initiative was instrumental in preparing nursing and clinical staff for the challenges of managing care and follow-up of patients undergoing CAR-T therapy.

Checkpoint Inhibitors Appear Safe for Pediatric Cancer Patients

Checkpoint Inhibitors Appear Safe for Pediatric Cancer Patients

By

The medications so far show little efficacy in children with cancer, but new studies may provide clues to how to change this, pediatric oncologist says.

Adjuvant + Neoadjuvant Pembrolizumab Safe in Patients Undergoing HNSCC Surgery

Adjuvant + Neoadjuvant Pembrolizumab Safe in Patients Undergoing HNSCC Surgery

By

Study also provides evidence supporting an anti-tumor effect associated with a single preoperative dose of pembrolizumab.

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

By

Children with extramedullary relapse of CD19+ acute lymphoblastic leukemia experienced a potent and durable response to the immunotherapy.

Autologous T-Cell Therapy Promising in Advanced Sarcoma

Autologous T-Cell Therapy Promising in Advanced Sarcoma

By

After lymphodepletion in patients with advanced HER2+ sarcoma, T cells expanded in 5 of 6 patients who received infusions of HER2-CAR T cells.

Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

By

Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.

Influenza Vaccination Increases Toxicity in PD-1/PD-L1 Immunotherapy Blockade for Lung Cancer

Influenza Vaccination Increases Toxicity in PD-1/PD-L1 Immunotherapy Blockade for Lung Cancer

By

Seasonal influenza vaccination was associated with increased rates of immunologic toxicity in patients with lung cancer receiving PD-1/PD-L1 immunotherapy blockade.

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

By

The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.

Nursing and Patient Education on Immunotherapy-related Adverse Events

Nursing and Patient Education on Immunotherapy-related Adverse Events

By

The unique adverse events related to treatment with immunotherapy require a proactive approach in the assessment of side effects and patient education.

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

By

A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.

Continuing Nivolumab After Progression of Head and Neck Cancer May Improve Survival

Continuing Nivolumab After Progression of Head and Neck Cancer May Improve Survival

By

Continuing immunotherapy after disease progression extends survival for some patients with head and neck cancer.

Prostate Cancer Response to Immunotherapy Improved With Combination Therapy

Prostate Cancer Response to Immunotherapy Improved With Combination Therapy

By

Immunotherapy alone is not effective in prostate cancer; however, combining it with PD-1/PD-L1 and VISTA inhibitors is effective.

Research Shows iPS-ML/IFN-β Migrates to, Penetrate Liver Cancer Tumors

Research Shows iPS-ML/IFN-β Migrates to, Penetrate Liver Cancer Tumors

By

Decreased liver tumor growth and improved survival in a mouse model were noted after injecting iPS-ML/IFN-β.

Pembrolizumab May Help Combat Mesothelioma

Pembrolizumab May Help Combat Mesothelioma

By

Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

By

Whole-exome sequencing of tumor biopsies explain low response rate to immunotherapy in metastatic melanoma.

Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer

Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer

By

Cabozantinib activated innate immunity and completely eradicated prostate cancer in a study using a mouse model.

Regorafenib Improves Quality-adjusted Survival in Sarcoma

Regorafenib Improves Quality-adjusted Survival in Sarcoma

By

In patients with soft tissue sarcoma pretreated with doxorubicin, treatment with regorafenib significantly reduced the risk of progression symptoms or toxicity.

Immunosuppressor Inhibits Metabolic Pathway in Breast Cancer, Kills Cancer Cells

Immunosuppressor Inhibits Metabolic Pathway in Breast Cancer, Kills Cancer Cells

By

Leflunomide, an immunosuppressor FDA-approved for rheumatoid arthritis, is effective against breast cancer in mouse study.

PI3K/mTOR Inhibitor Demonstrates Efficacy in Some Uterine Sarcomas

PI3K/mTOR Inhibitor Demonstrates Efficacy in Some Uterine Sarcomas

By

A new generation dual PI3K/mTOR inhibitor shows promise in treating leiomyosarcomas with the protein P-S6S240.

Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma

Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma

By

Rechallenge with dabrafenib plus trametinib demonstrated antitumor activity in patients who had previously progressed on BRAF inhibitor therapy.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs